Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports
Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.
MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity
Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.
Multiple Sclerosis Drugs Might Not Need To Reach the Brain To Have Clinical Efficacy
Source Technology Networks: Scientists from Trinity College Dublin have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS) and other autoimmune diseases such as psoriasis and rheumatoid arthritis.
Gene Variants Linked to High Childhood BMI Point to Higher MS Risk, Study Finds
Source Multiple Sclerosis News Today: Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS) regardless of a person’s vitamin D levels, a study found.
Sanofi MS drug results set stage for extensive late-stage testing
Source Biopharmadive.com: With positive results from a mid-stage study in hand, Sanofi is pushing an experimental multiple sclerosis drug into an extensive late-stage research program comprised of four studies scheduled to begin in the middle of this year.
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART)
Source The Lancet: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource.
Siponimod licensed for secondary progressive MS
Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.
New Study Asks: When Does MS Begin?
Source National Multiple Sclerosis Society: Researchers from the Harvard T.H. Chan School of Public Health in Boston and collaborators report on a study that examined blood (serum) samples from 60 military personnel who went on to develop multiple sclerosis years later. Compared to samples from...
MS Progression Affected by Degree of Relapse Recovery and Timing of DMT Use, Study Says
Source Multiple Sclerosis News Today: Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterwards considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests.
Its findings support relapse...
From depression to dementia, inflammation is medicine’s new frontier
Source The Guardian: The barrier between mind and body appears to be crumbling. Clinical practice and public perception need to catch up.
Unlikely as it may seem, #inflammation has become a hashtag. It seems to be everywhere suddenly, up to all sorts of tricks. Rather than simply being...
Pages
